INS and type 2 diabetes mellitus: The Treating to Target in Type 2 Diabetes (4-T) study revealed that the addition ofanalog biphasic, prandial, or basal insulin to maximal tolerated doses of metformin or an SU inpatients with suboptimal glycemic control was associated with clinically relevant andsustainable reductions in HbA1c.3 Moreover, thebiphasic and prandial regimens lowered HbA1c to the same extent and to a greater degree than thebasal regimens.